BioLineRx stock maintains buy rating at H.C. Wainwright on cancer data

H.C. Wainwright reiterated its Buy rating and $26 price target on BioLineRx (BLRX) after the company presented positive Phase 2 trial data for motixafortide in metastatic pancreatic cancer, showing a 64% overall response rate and a 91% disease control rate, significantly outperforming historical controls; the trial is expanding into a randomized study. Jones Trading upgraded BLRX to Buy, while another note maintained a Hold rating, citing the need for further pipeline development. BioLineRx reported better-than-expected Q1 2025 earnings of $1.39 per share and ended the quarter with $26.4 million in cash, expected to fund operations into the second half of 2026; however, InvestingPro data indicates the company is burning through cash.

Analysis

BioLineRx (NASDAQ:BLRX) has presented encouraging full data from the pilot phase of its CheMo4METPANC Phase 2 trial for motixafortide in metastatic pancreatic ductal adenocarcinoma, demonstrating a 64% overall response rate and a 91% disease control rate in 11 treatment-naïve patients. These figures significantly surpass historical controls, which typically report 23% and 48% respectively. Notably, four patients remained progression-free for over a year, and the study supported motixafortide's mechanism of action through observed increases in intratumoral CD8+ T cell infiltration. Consequently, H.C. Wainwright reiterated its Buy rating and $26.00 price target. The company plans to advance to a randomized, open-label Phase 2 study with 108 patients, targeting full enrollment by 2027. Financially, BioLineRx reported better-than-expected Q1 2025 earnings per share of $1.39, largely due to warrant accounting, and ended the quarter with $26.4 million in cash, projected to fund operations into the second half of 2026. Revenue of $0.3 million was generated from APHEXDA royalties. However, InvestingPro data highlights a significant cash burn, with negative free cash flow of $32.38 million over the last twelve months, despite a healthy current ratio of 2.27. While Jones Trading recently upgraded the stock to Buy based on this data, another note from the same firm maintained a Hold, emphasizing the need for broader pipeline development. The stock, currently trading at $4.67, is substantially below its 52-week high of $35.60, though analyst price targets range from $12 to $40.

Key Decisions for Investors

• Investors should weigh the highly promising Phase 2 clinical trial results for motixafortide against the company's significant cash burn rate and early stage of revenue generation.
• Monitor the progress of the expanded randomized Phase 2 trial closely, as its outcomes and enrollment pace will be critical valuation catalysts, alongside the company's cash management and potential future financing requirements.
• Consider the speculative nature of the investment; while the disparity between the current stock price and analyst targets suggests considerable upside if clinical success is achieved, the mixed analyst sentiment regarding broader pipeline needs and the inherent risks of drug development warrant careful risk assessment.